Skip to main content
Premium Trial:

Request an Annual Quote

Commugene to Distribute Qlucore's Software in South Korean Market

Premium

NEW YORK (GenomeWeb) – Qlucore has signed an agreement with Commugene that lets the latter distribute its Qlucore Omics Explorer software to clients in the South Korean biotechnology and pharmaceutical markets.

"We are delighted to be entering into this agreement with Commugene," Carl-Johan Ivarsson, Qlucore's president said in a statement. "We are confident that this cooperation will help researchers in South Korea to learn more about our software, and to achieve extraordinary results with their data analysis."

"The biotech and pharmaceutical sectors in South Korea are growing very quickly, which means that there is a strong demand for truly innovative solutions in these areas," Jeong-hun Kim, Commugene's director of marketing and sales, added "We have no doubt that Qlucore Omics Explorer will be very attractive to the scientific community in South Korea."

Financial and other terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.